Author

Joy Garrett

Indiana University School of Medicine

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:CUT&Tag· 1 Approach:genetic perturbation / CRISPR· 1 Assay:proteomics· 1

Frequent Co-Authors

John J. TurchiiD· 2 shared Jun WaniD· 2 shared Matthew R. JordaniD· 2 shared Sheng LiuiD· 2 shared Hilary D. Hinshaw· 1 shared Jessica Lynn Kersey· 1 shared Karen E. PollokiD· 1 shared Katherine S. PawelczakiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

John J. TurchiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

PARP1 catalytic domain mutations drive high-level resistance to saruparib while preserving DNA damage response vulnerabilities

Matthew R. Jordan, Jessica Lynn Kersey, Joy Garrett, Sheng Liu, Jun Wan, John J. Turchi

This study identifies PARP1 catalytic domain mutations as a mechanism of high-level resistance to saruparib in BRCA1-deficient breast cancer cells, while retaining DDR vulnerabilities.

bioRxiv · May 13, 2026 · PreprintCancer Biology

Chemical inhibition of RPA gap protection sensitizes BRCA1-deficient cancers to PARP inhibition

Pamela S. VanderVere-Carozza, Matthew R. Jordan, Joy Garrett, Karen E. Pollok, Hilary D. Hinshaw, Xierzhatijiang Sulaiman, Sheng Liu, Jun Wan, Katherine S. Pawelczak, John J. Turchi

This study shows that inhibiting RPA gap protection enhances PARP inhibitor efficacy in BRCA1-deficient cancers by increasing genomic instability and reducing tumor growth.

bioRxiv · Apr 9, 2025 · PreprintCancer Biology